UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 29, 2026
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE/27
New York Stock Exchange
2.875% Notes due 2029
PFE/29
New York Stock Exchange
3.250% Notes due 2032
PFE/32
New York Stock Exchange
3.875% Notes due 2037
PFE/37A
New York Stock Exchange
4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At April 29, 2026, 5,699,444,169 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
32
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
46
Item 4.
Controls and Procedures
46
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
46
Item 1A.
Risk Factors
46
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
46
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other Information
46
Item 6.
Exhibits
47
Signature
47
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 22, 2026 and February 23, 2025, and for U.S. subsidiaries is as of and for the three months ended March 29, 2026 and March 30, 2025. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2025 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
Indicates calculation not meaningful or results are greater than 100%
2025 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2025
340B Program340B Drug Pricing Program
3SBio3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd.
AIartificial intelligence
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BMSBristol-Myers Squibb Company
BODBoard of Directors
CODMChief Operating Decision Maker
ComirnatyUnless otherwise noted, refers to, as applicable, the current formulation of Comirnaty (COVID-19 Vaccine, mRNA) 2025-2026 Formula as well as all prior authorized or approved formulations of the vaccine, which was first authorized in the U.S. during December 2020 pursuant to an EUA
COVID-19novel coronavirus disease of 2019
Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Nordic countries, Australia, certain Eastern European countries, South Korea and New Zealand
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans and certain other countries), Africa, Turkey and the Middle East
EPSearnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2026
GAAPU.S. Generally Accepted Accounting Principles
GILTI (NCTI)Global Intangible Low-Taxed Income (renamed Net Controlled Foreign Corporation (CFC) Tested Income (NCTI) for taxable years starting after December 31, 2025)
GSKGSK plc
HaleonHaleon plc
HospiraHospira, Inc.
HRRhomologous recombination repair
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
mCCmetastatic cervical cancer
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
Medicare Part Da prescription drug coverage program for people with Medicare
MetseraMetsera, Inc.
Moody sMoody s Ratings (formerly Moody s Investors Service)
mRNAmessenger ribonucleic acid
nmCRPCnon-metastatic castration-resistant prostate cancer
nmCSPCnon-metastatic castration-sensitive prostate cancer
NSCLCnon-small cell lung cancer
OBBBAOne Big Beautiful Bill Act
ODToral disintegrating tablet
OTCover-the-counter
Paxlovid(a)
an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
Prevnar familyIncludes Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)
PsApsoriatic arthritis
RArheumatoid arthritis
R&Dresearch and development
RSVrespiratory syncytial virus
S&PS&P Global (formerly Standard & Poor s)
Sciwind Biosciences
Hangzhou Sciwind Biosciences Co., Ltd.
SeagenSeagen Inc. and its subsidiaries
SECU.S. Securities and Exchange Commission
SI&ASelling, informational and administrative expenses
TakedaTakeda Pharmaceutical Company Limited
Tax Cuts and Jobs Act or TCJALegislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
UCulcerative colitis
U.K.United Kingdom
U.S.United States
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
WyethWyeth LLC (formerly Wyeth)
YaoPharmaYaoPharma Co., Ltd.
(a)Paxlovid has not been approved, but has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, 21 U.S.C. 360bbb-3(b)(1) unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheet at www.covid19oralrx.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)March 29,
2026March 30,
2025
Revenues:
Product revenues
$11,715 $11,294
Alliance revenues
2,339 2,113
Royalty revenues
396 308
Total revenues14,451 13,715
Costs and expenses:
Cost of sales(a)
3,548 2,845
Selling, informational and administrative expenses(a)
2,961 3,031
Research and development expenses(a)
2,490 2,203
Acquired in-process research and development expenses137 9
Amortization of intangible assets1,183 1,211
Restructuring charges and certain acquisition-related costs100 678
Other (income)/deductions net861 953
Income from continuing operations before provision/(benefit) for taxes on income3,170 2,785
Provision/(benefit) for taxes on income461 (189)
Income from continuing operations2,709 2,973
Discontinued operations net of tax(13)
Net income before allocation to noncontrolling interests2,696 2,973
Less: Net income attributable to noncontrolling interests8 6
Net income attributable to Pfizer Inc. common shareholders$2,687 $2,967
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.48 $0.52
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.47 $0.52
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
$0.47 $0.52
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.47 $0.52
Weighted-average shares basic5,691 5,675
Weighted-average shares diluted5,731 5,710
(a) Exclusive of amortization of intangible assets.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Net income before allocation to noncontrolling interests$2,696 $2,973
Foreign currency translation adjustments, net923 (557)
Unrealized holding gains/(losses) on derivative financial instruments, net(36)(123)
Reclassification adjustments for (gains)/losses included in net income(a)
9 (313)
(27)(436)
Unrealized holding gains/(losses) on available-for-sale securities, net38 (31)
Reclassification adjustments for (gains)/losses included in net income(b)
21 155
60 124
Reclassification adjustments related to amortization of prior service costs and other, net(7)(30)
Reclassification adjustments related to curtailments of prior service costs and other, net(5)(33)
(12)(64)
Other comprehensive income/(loss), before tax944 (932)
Tax provision/(benefit) on other comprehensive income/(loss)81 (191)
Other comprehensive income/(loss) before allocation to noncontrolling interests$863 $(741)
Comprehensive income/(loss) before allocation to noncontrolling interests$3,559 $2,232
Less: Comprehensive income/(loss) attributable to noncontrolling interests5 4
Comprehensive income/(loss) attributable to Pfizer Inc.$3,554 $2,229
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)March 29,
2026December 31, 2025
(Unaudited)
Assets
Cash and cash equivalents$1,703 $1,142
Short-term investments11,372 12,454
Trade accounts receivable, net of allowance for doubtful accounts: 2026 $425; 2025 $427
12,585 11,874
Inventories10,667 10,654
Current tax assets3,588 3,967
Other current assets2,908 2,808
Total current assets42,822 42,898
Long-term investments1,626 1,621
Property, plant and equipment, net of accumulated depreciation: 2026 $17,803; 2025 $17,386
19,402 19,317
Identifiable intangible assets, net
52,559 53,731
Goodwill71,409 71,264
Noncurrent deferred tax assets and other noncurrent tax assets9,965 9,699
Other noncurrent assets9,834 9,631
Total assets$207,618 $208,160
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2026 $3,861; 2025 $2,997
$3,890 $3,154
Trade accounts payable4,506 5,240
Dividends payable 2,445
Income taxes payable3,130 3,103
Accrued compensation and related items2,715 3,610
Other current liabilities20,108 19,432
Total current liabilities34,348 36,984
Long-term debt60,565 61,641
Pension and postretirement benefit obligations1,984 2,041
Noncurrent deferred tax liabilities2,412 2,401
Other taxes payable3,705 3,591
Other noncurrent liabilities14,200 14,725
Total liabilities117,214 121,385
Commitments and Contingencies
Common stock482 481
Additional paid-in capital94,773 94,469
Treasury stock(115,190)(115,015)
Retained earnings117,238 114,610
Accumulated other comprehensive loss(7,203)(8,069)
Total Pfizer Inc. shareholders equity90,101 86,476
Equity attributable to noncontrolling interests303 299
Total equity90,404 86,775
Total liabilities and equity$207,618 $208,160
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20269,621 $481 $94,469 (3,935)$(115,015)$114,610 $(8,069)$86,476 $299 $86,775
Net income
2,687 2,687 8 2,696
Other comprehensive income/(loss), net of tax
867 867 (4)863
Cash dividends declared, per share: $
Common stock
Share-based payment transactions20 1 304 (7)(176)(60)70 70
Other 1 1 1
Balance, March 29, 20269,641 $482 $94,773 (3,942)$(115,190)$117,238 $(7,203)$90,101 $303 $90,404
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497
Net income
2,967 2,967 6 2,973
Other comprehensive income/(loss), net of tax(738)(738)(3)(741)
Cash dividends declared, per share: $
Common stock
Share-based payment transactions27 1 252 (9)(245)(103)(94)(94)
Other 1 1 2 2
Balance, March 30, 20259,620 $481 $93,856 (3,935)$(115,008)$119,590 $(8,581)$90,338 $299 $90,637
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Operating Activities
Net income before allocation to noncontrolling interests$2,696 $2,973
Discontinued operations net of tax(13)
Net income from continuing operations before allocation to noncontrolling interests2,709 2,973
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization1,613 1,618
Asset write-offs and impairments32 344
Deferred taxes(12)(663)
Share-based compensation expense272 170
Benefit plan contributions in excess of expense/income(173)(229)
Other adjustments, net(93)40
Other changes in assets and liabilities, net of acquisitions and divestitures(1,732)(1,919)
Net cash provided by/(used in) operating activities2,615 2,335
Investing Activities
Purchases of property, plant and equipment(436)(564)
Purchases of short-term investments(2,569)(2,823)
Proceeds from redemptions/sales of short-term investments4,576 3,955
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(792)(3,852)
Purchases of long-term investments(104)(134)
Proceeds from redemptions/sales of long-term investments88 82
Proceeds from sales of investment in Haleon
6,311
Other investing activities, net22 300
Net cash provided by/(used in) investing activities785 3,274
Financing Activities
Payments on short-term borrowings (2,048)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(127)(386)
Cash dividends paid(2,445)(2,437)
Other financing activities, net(284)(356)
Net cash provided by/(used in) financing activities(2,856)(5,227)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
19 (7)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents563 375
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,197 1,107
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,760 $1,481
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
$72 $152
Interest paid
293 353
Interest rate hedges62 74
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2025 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2025 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 22, 2026 and February 23, 2025, and for U.S. subsidiaries is as of and for the three months ended March 29, 2026 and March 30, 2025.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and PC1. Biopharma is the only reportable segment. See Note 13A.
B. Revenues and Trade Accounts Receivable
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)March 29,
2026December 31, 2025
Reserve against Trade accounts receivable, net of allowance for doubtful accounts
$1,699 $1,803
Other current liabilities:
Accrued rebates8,846 7,909
Other accruals718 750
Other noncurrent liabilities
287 1,204
Total accrued rebates and other sales-related accruals$11,550 $11,666
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market, delinquency status, and customer type (high risk versus low risk and government versus non-government), and reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three months ended March 29, 2026 and March 30, 2025, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.
For additional information on our trade accounts receivable, see Note 1G in our 2025 Form 10-K.
Note 2. Acquisition, In-Licensing Arrangement and Sale of Investment
A. Acquisition
Metsera On November 13, 2025, we acquired Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, for $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share in potential additional payments (up to $2.3 billion) tied to the achievement of three specified milestones: $4.60 per share following the Phase 3 clinical trial start of Metsera s injectable GLP-1 receptor antagonist MET-097i+amylin analog MET-233i combination, $6.40 per share following FDA approval of Metsera s monthly MET-097i monotherapy and $9.65 per share following FDA approval of Metsera s monthly MET-097i+MET-233i combination. The total fair value of the consideration transferred was $8.0 billion ($7.8 billion net of cash acquired), which includes the fair value of $632 million for the noncash CVRs and $475 million for employee stock awards related to pre-acquisition service.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In connection with this business combination, we provisionally recorded: (i) $8.0 billion of identifiable intangible assets, net, consisting of IPR&D, (ii) $2.0 billion of Goodwill, (iii) $1.6 billion of net deferred tax liabilities, and (iv) $672 million of contingent consideration liability assumed from Metsera. Goodwill, which resulted primarily from the recognition of deferred tax liabilities, is related to our Biopharma segment and is not deductible for tax purposes. The contingent consideration liability was recorded at fair value and relates to Metsera s 2023 acquisition of Zihipp Ltd (Zihipp). As a part of that transaction, the former Zihipp shareholders are entitled to future potential development, regulatory and commercialization milestone payments, along with low-single digit royalties on net product sales on the MET-097i and MET-233i product candidates. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
B. In-Licensing Arrangement
In-Licensing Arrangement with Sciwind Biosciences In February 2026, Pfizer and Sciwind Biosciences announced a strategic commercialization collaboration in which Pfizer obtained exclusive commercialization rights for Sciwind Biosciences glucagon-like peptide 1 (GLP-1) receptor agonist ecnoglutide in Mainland China. Sciwind Biosciences remains the Marketing Authorization Holder and is responsible for R&D, registration, manufacturing and supply of the product. Sciwind Biosciences is eligible to receive an aggregate of up to $495 million in upfront, regulatory and sales milestone payments.
C. Sale of Investment
ViiV On March 31, 2026, which fell in our second fiscal quarter of 2026, Pfizer completed the exit of its 11.7% investment in ViiV (carrying value of zero) and received $1.875 billion in cash proceeds. See Note 2C in our 2025 Form 10-K.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning Our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes.
We expect costs associated with these components of the program to be incurred through 2027 and to total approximately $4.7 billion, representing primarily cash expenditures for severance, implementation, exit, and digital enablement costs, as well as non-cash asset write downs of which $3.1 billion is associated with our Biopharma segment.
Additionally, in connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in 2025, with cash outlays expected primarily through 2026.
We expect costs associated with all the components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.
From the start of this program through March 29, 2026, we incurred total costs of $4.3 billion, of which $3.3 billion is associated with our Biopharma segment (including $2.9 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which includes operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is primarily focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through March 29, 2026, we incurred costs of $1.1 billion (including $853 million of restructuring charges). These costs were recorded primarily through 2025, with cash outlays expected primarily through 2026.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Restructuring charges/(credits):
Employee terminations$15 $384
Asset impairments28 173
Exit costs
6 64
Restructuring charges/(credits)(a)
49 621
Integration costs and other(b)
51 57
Restructuring charges and certain acquisition-related costs100 678
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
3 (59)
Additional depreciation asset restructuring recorded in Cost of sales(c)
3 4
Implementation costs recorded in our condensed consolidated statements of operations as follows(d):
Cost of sales15 20
Selling, informational and administrative expenses36 6
Research and development expenses38 24
Total implementation costs89 50
Total costs associated with acquisitions and cost-reduction/productivity initiatives$195 $673
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
(b)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(c)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(d)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2025(a)
$1,783 $ $127 $1,910
Provision
15 28 6 49
Utilization and other(b)
(330)(28)(12)(371)
Balance, March 29, 2026(c)
$1,467 $ $121 $1,588
(a)Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Interest income$(115)$(143)
Interest expense668 654
Net interest expense
554 511
Net (gains)/losses recognized during the period on equity securities
9 370
Net periodic benefit costs/(credits) other than service costs(72)(158)
Certain legal matters, net(a)
191 142
Certain asset impairments(b)
224
Changes in fair value of contingent consideration liabilities(c)
295 8
Other, net
(116)(144)
Other (income)/deductions net
$861 $953
(a)The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(b)The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
(c)See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 14.6% for the first quarter of 2026, compared to (6.8)% for the first quarter of 2025. The increase in the effective tax rate for the first quarter of 2026, compared to the first quarter of 2025, was primarily due to an unfavorable change in the jurisdictional mix of earnings, and non-recurrence of favorable global income tax resolutions.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The eighth and final annual installment was paid by its April 15, 2026 due date and was reported in current Income taxes payable as of March 29, 2026. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
See Note 5A in our 2025 Form 10-K for information on our income taxes paid (net of refunds received).
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit. Tax years 2023-2026 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2016.
See Note 5D in our 2025 Form 10-K.
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Foreign currency translation adjustments, net(a)
$76 $(102)
Unrealized holding gains/(losses) on derivative financial instruments, net(5)(34)
Reclassification adjustments for (gains)/losses included in net income
6 (55)
(89)
Unrealized holding gains/(losses) on available-for-sale securities, net5 (4)
Reclassification adjustments for (gains)/losses included in net income
3 19
7 15
Reclassification adjustments related to amortization of prior service costs and other, net(2)(7)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)(9)
(3)(16)
Tax provision/(benefit) on other comprehensive income/(loss)
$81 $(191)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2026
$(7,796)$(321)$(28)$75 $(8,069)
Other comprehensive income/(loss)(b)
851 (27)52 (9)867
Balance, March 29, 2026$(6,944)$(348)$24 $66 $(7,203)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy:
March 29, 2026December 31, 2025
(MILLIONS)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$1,865 $ $1,865 $ $2,596 $ $2,596 $
Available-for-sale debt securities:
Government and agency non-U.S.
3,888 3,888 4,859 4,859
Government and agency U.S.
2,935 2,935 3,030 3,030
Corporate and other
1,366 1,366 1,294 1,294
8,189 8,189 9,183 9,183
Total short-term investments10,054 10,054 11,779 11,779
Other current assets
Derivative assets:
Interest rate contracts
6 6
Foreign exchange contracts
498 498 416 416
Total other current assets504 504 416 416
Long-term investments
Equity securities with readily determinable fair values(b)
653 653 642 642
Available-for-sale debt securities:
Government and agency non-U.S.
1 1
Corporate and other
1 1
Total long-term investments653 653 642 642 1
Other noncurrent assets
Derivative assets:
Interest rate contracts
27 27 52 52
Foreign exchange contracts
128 128 64 64
Total derivative assets155 155 116 116
Insurance contracts(c)
950 950 999 999
Total other noncurrent assets1,105 1,105 1,115 1,115
Total assets$12,315 $653 $11,663 $ $13,953 $642 $13,311 $
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$1 $ $1 $ $16 $ $16 $
Foreign exchange contracts
283 283 412 412
Contingent consideration liabilities(d)
95 95 95 95
Total other current liabilities379 284 95 523 428 95
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts275 275 215 215
Foreign exchange contracts
807 807 815 815
Contingent consideration liabilities(d)
1,946 1,946 1,695 1,695
Total other noncurrent liabilities3,027 1,081 1,946 2,725 1,030 1,695
Total liabilities$3,406 $ $1,365 $2,041 $3,248 $ $1,458 $1,790
(a)Includes money market funds primarily invested in U.S. Treasury and government debt.
(b)Long-term equity securities of $147 million as of March 29, 2026 and $146 million as of December 31, 2025 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
(d)Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Notes 1D and 16D in our 2025 Form 10-K and Note 2A for additional information on contingent consideration liabilities).
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following provides the changes in our contingent consideration liabilities valued using significant unobservable inputs:
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Fair value, beginning$1,790 $517
Changes in estimated fair value(a)
295 8
Additions
Settlements and other
(45)(48)
Transfer into/(out of) Level 3
Fair value, ending$2,041 $477
(a)Reported in Other (income)/deductions net. See Note 4. The amount in the first quarter of 2026 is primarily related to our acquisition of Metsera.
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $61 billion as of March 29, 2026 and $62 billion as of December 31, 2025. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $58 billion as of March 29, 2026 and $60 billion as of December 31, 2025.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 29, 2026 and December 31, 2025. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term and Long-Term Investments
The following summarizes our investments by classification type:
(MILLIONS)March 29,
2026 December 31, 2025
Short-term investments
Equity securities with readily determinable fair values
$1,865 $2,596
Available-for-sale debt securities8,189 9,183
Held-to-maturity debt securities1,318 675
Total Short-term investments$11,372 $12,454
Long-term investments
Equity securities with readily determinable fair values(a)
$653 $642
Available-for-sale debt securities 1
Held-to-maturity debt securities47 48
Private equity securities at cost(a)
688 696
Equity-method investments237 235
Total Long-term investments$1,626 $1,621
(a)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
March 29, 2026December 31, 2025
Gross Unrealized Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$3,860 $29 $(2)$3,888 $3,888 $ $ $4,890 $3 $(34)$4,859
Government and agency U.S.
2,935 2,935 2,935 3,030 3,030
Corporate and other1,366 1,366 1,366 1,295 (1)1,294
Held-to-maturity debt securities
Corporate, time deposits and other
756 756 710 9 37 487 487
Government and agency non-U.S.
610 610 608 1 236 236
Total debt securities$9,526 $29 $(2)$9,554 $9,507 $10 $38 $9,938 $3 $(35)$9,906
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025
Net (gains)/losses recognized during the period on equity securities(a)
$9 $370
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(6)(924)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date
$15 $1,295
(a)Reported in Other (income)/deductions net. See Note 4.
Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 29, 2026, there were cumulative impairments and downward adjustments of $444 million and upward adjustments of $225 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2026 and 2025.
C. Short-Term Borrowings
Short-term borrowings include:
(MILLIONS) March 29,
2026 December 31, 2025
Current portion of long-term debt, principal amount$3,864 $3,000
Other short-term borrowings, principal amount(a)
29 157
Total short-term borrowings, principal amount
3,893 3,157
Net unamortized discounts, premiums and debt issuance costs(3)(3)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted
$3,890 $3,154
(a)Primarily includes cash collateral. See Note 7F.
D. Long-Term Debt
The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:
(MILLIONS)March 29,
2026 December 31, 2025
Total long-term debt, principal amount$60,313 $61,293
Net fair value adjustments related to hedging and purchase accounting726 834
Net unamortized discounts, premiums and debt issuance costs(473)(486)
Total long-term debt, carried at historical proceeds, as adjusted$60,565 $61,641
E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Chinese renminbi, Japanese yen, Canadian dollar, and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may also seek to protect against possible declines in the net investments of our foreign business entities.
Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest
17
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.
The following summarizes the fair value of the derivative financial instruments and notional amounts:
March 29, 2026December 31, 2025
Fair ValueFair Value
(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability
Derivatives designated as hedging instruments:
Foreign exchange contracts(a)
$23,593 $517 $942 $22,984 $325 $1,066
Interest rate contracts7,995 33 276 6,750 52 230
550 1,218 377 1,296
Derivatives not designated as hedging instruments:
Foreign exchange contracts$17,134 109 147 $22,777 155 162
Total$659 $1,365 $532 $1,458
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 29, 2026 and $5.0 billion as of December 31, 2025.
The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:
Gains/(Losses)
Recognized in OID(a)
Gains/(Losses)
Recognized in OCI(a)
Gains/(Losses)
Reclassified from
OCI into OID and COS(a)
Three Months Ended
(MILLIONS)March 29,
2026March 30,
2025March 29,
2026March 30,
2025March 29,
2026March 30,
2025
Derivative Financial Instruments in Cash Flow Hedge Relationships:
Interest rate contracts$ $ $ $ $ $2
Foreign exchange contracts(b)
(48)(138)(21)295
Amount excluded from effectiveness testing and amortized into earnings(c)
12 15 12 16
Derivative Financial Instruments in Fair Value Hedge Relationships:
Interest rate contracts(85)142
Hedged item 85 (142)
Derivative Financial Instruments in Net Investment Hedge Relationships:
Foreign exchange contracts 240 (437)
Amount excluded from effectiveness testing and amortized into earnings(c)
47 75 53 41
Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):
Foreign currency short-term borrowings 18
Foreign currency long-term debt (2)(31)
Derivative Financial Instruments Not Designated as Hedges:
Foreign exchange contracts(13)(31)
$(13)$(31)$267 $(517)$44 $354
(a)OID = Other (income)/deductions net, included in Other (income)/deductions net in the condensed consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income/(loss).
(b)The amounts reclassified from OCI into COS were a net loss of $14 million in the first quarter of 2026 and a net gain of $62 million in the first quarter of 2025. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $9 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 17 years and relates to foreign currency debt.
(c)The amounts reclassified from OCI were reclassified into OID.
(d)Long-term debt includes foreign currency borrowings, which are used in net investment hedges; the related carrying values as of March 29, 2026 and December 31, 2025 were $863 million and $879 million, respectively.